131 related articles for article (PubMed ID: 8299367)
21. 0.05% clobetasol 17-propionate cream and ointment but not the corresponding 0.1% triamcinolone acetonide preparations increase skin surface roughness: a possible dissociation of unwanted epidermal and dermal effects.
Kerscher MJ; Korting HC; Mehringer L; Mätzig R
Skin Pharmacol; 1996; 9(2):120-3. PubMed ID: 8722606
[TBL] [Abstract][Full Text] [Related]
22. Fatal iatrogenic Cushing's syndrome.
Nathan AW; Rose GL
Lancet; 1979 Jan; 1(8109):207. PubMed ID: 84219
[No Abstract] [Full Text] [Related]
23. Objective determination of the bioavailability of dermocorticoids--influence of the formulation.
Poelman MC; Leveque JL; Le Gall F
Br J Dermatol; 1984 Jul; 111 Suppl 27():158-62. PubMed ID: 6743548
[TBL] [Abstract][Full Text] [Related]
24. New experimental approach to measure the skin-reflected light. Application to cutaneous erythema and blanching.
Lévêque JL; Poelman MC; Legall F; de Rigal J
Dermatologica; 1985; 170(1):12-6. PubMed ID: 3972145
[TBL] [Abstract][Full Text] [Related]
25. Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Enhanced Lotion Formulation of Halobetasol Propionate, 0.05% Versus Its Vehicle in Adult Subjects With Plaque Psoriasis.
Pariser D; Bukhalo M; Guenthner S; Kempers S; Shideler S; Gold LS; Tschen E; Berg J; Ferdon MB; Dromgoole S
J Drugs Dermatol; 2017 Mar; 16(3):234-240. PubMed ID: 28301619
[TBL] [Abstract][Full Text] [Related]
26. Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids.
Schäfer-Korting M; Korting HC; Kerscher MJ; Lenhard S
Clin Pharmacol Ther; 1993 Oct; 54(4):448-56. PubMed ID: 8222488
[TBL] [Abstract][Full Text] [Related]
27. Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis.
Decroix J; Pres H; Tsankov N; Poncet M; Arsonnaud S
Cutis; 2004 Sep; 74(3):201-6. PubMed ID: 15499763
[TBL] [Abstract][Full Text] [Related]
28. Are the Spanish baseline series markers sufficient to detect contact allergy to corticosteroids in Spain? A GEIDAC prospective study.
Mercader-García P; Pastor-Nieto MA; García-Doval I; Giménez-Arnau A; González-Pérez R; Fernández-Redondo V; Serra-Baldrich E; Cordoba-Guijarro S; Gatica-Ortega ME; Silvestre-Salvador JF;
Contact Dermatitis; 2018 Jan; 78(1):76-82. PubMed ID: 28960334
[TBL] [Abstract][Full Text] [Related]
29. A comparison of the potencies of several diluted and undiluted corticosteroid preparations using the vasoconstrictor assay.
Kirsch J; Gibson JR; Darley CR; Burke CA
Dermatologica; 1983; 167(3):138-41. PubMed ID: 6195026
[TBL] [Abstract][Full Text] [Related]
30. The effects of intradermal steroids on the pituitary-adrenal axis and the skin.
Jarratt MT; Spark RF; Arndt KA
J Invest Dermatol; 1974 Apr; 62(4):463-6. PubMed ID: 4820688
[No Abstract] [Full Text] [Related]
31. Steroid addiction.
Kligman AM; Frosch PJ
Int J Dermatol; 1979; 18(1):23-31. PubMed ID: 153891
[No Abstract] [Full Text] [Related]
32. Topical glucocorticoids of the non-fluorinated double-ester type. Lack of atrophogenicity in normal skin as assessed by high-frequency ultrasound.
Kerscher MJ; Korting HC
Acta Derm Venereol; 1992; 72(3):214-6. PubMed ID: 1357864
[TBL] [Abstract][Full Text] [Related]
33. Validation of Dermaphot(®) for the assessment of steroid-induced skin atrophy.
Hofmann M; Salgo R; Aschoff R; Luger TA; Meurer M; Bräutigam M; Thaci D
Arch Dermatol Res; 2013 Apr; 305(3):215-21. PubMed ID: 23242470
[TBL] [Abstract][Full Text] [Related]
34. Are the effects of local treatment with glucocorticoids only local?
van Tuyl SA; Slee PH
Neth J Med; 2002 Apr; 60(3):130-2. PubMed ID: 12164369
[No Abstract] [Full Text] [Related]
35. [Reducing the dosage by new technology].
Steinhorst M
Hautarzt; 2001 Jan; 52(1):p following 90 (91). PubMed ID: 11220248
[No Abstract] [Full Text] [Related]
36. Comparison of the effects of calcipotriol, prednicarbate and clobetasol 17-propionate on normal skin assessed by ultrasound measurement of skin thickness.
Lévy J; Gassmüller J; Schröder G; Audring H; Sönnichsen N
Skin Pharmacol; 1994; 7(4):231-6. PubMed ID: 8024805
[TBL] [Abstract][Full Text] [Related]
37. Topical clobetasol for the treatment of toxic epidermal necrolysis: study protocol for a randomized controlled trial.
Wilken R; Li CS; Sharon VR; Kim K; Patel FB; Patel F; Maverakis E
Trials; 2015 Aug; 16():374. PubMed ID: 26297574
[TBL] [Abstract][Full Text] [Related]
38. Dramatic hyperpigmentation of keloids after intralesional triamcinolone acetonide injection.
Koh WL; Lim SP
Dermatol Online J; 2015 May; 21(5):. PubMed ID: 26295862
[No Abstract] [Full Text] [Related]
39. Contact sensitivity to betamethasone 17-valerate and fluocinolone acetonide.
Pasricha JS; Gupta R
Contact Dermatitis; 1983 Jul; 9(4):330-1. PubMed ID: 6225621
[No Abstract] [Full Text] [Related]
40. Bioavailability of clobetasol propionate in different vehicles.
Franz TJ; Lehman PA; Feldman SR; Spellman MC
Skin Pharmacol Appl Skin Physiol; 2003; 16(4):212-6. PubMed ID: 12784060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
